Based on our results we predict IGF-1R/IR inhibitors may fail to enhance therapy responses in p53 wild-type cancers due to the potentially opposing effects of reducing p53-dependent senescence while increasing p53-dependent apoptosis. Here, IGF1R is linked to cancer.